About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

PARP Inhibitor BRCA Breast Cancer Trials

 

PARP Inhibitor Breast Cancer Clinical Trials for BRCA Mutation Carriers

The below are PARP inhibitor studies currently open to breast cancer patients with a known BRCA mutation regardless of the ER/PR status of the tumor. If you have a BRCA mutation and also have triple-negative breast cancer, you may also qualify for studies enrolling triple-negative patients. Please visit our triple-negative breast cancer study page for a list of those trials. Other eligibility criteria may apply; for more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.


 

Page updated 11/30/11

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org